Journal article
Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimer's disease
Nature communications, Vol.12(1), pp.4001-4001
06/28/2021
DOI: 10.1038/s41467-021-24220-7
PMCID: PMC8238986
PMID: 34183654
Abstract
Neuroinflammation is associated with Alzheimer's disease, but the application of cerebrospinal fluid measures of inflammatory proteins may be limited by overlapping pathways and relationships between them. In this work, we measure 15 cerebrospinal proteins related to microglial and T-cell functions, and show them to reproducibly form functionally-related groups within and across diagnostic categories in 382 participants from the Alzheimer's Disease Neuro-imaging Initiative as well participants from two independent cohorts. We further show higher levels of proteins related to soluble tumor necrosis factor receptor 1 are associated with reduced risk of conversion to dementia in the multi-centered (p=0.027) and independent (p=0.038) cohorts of people with mild cognitive impairment due to predicted Alzheimer's disease, while higher soluble TREM2 levels associated with slower decline in the dementia stage of Alzheimer's disease. These inflammatory proteins thus provide prognostic information independent of established Alzheimer's markers. Neuroinflammation is observed in Alzheimer's disease. Here the authors show that 15 proteins related to inflammation found in CSF can potentially be used as a prognostic biomarker.
Details
- Title: Subtitle
- Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimer's disease
- Creators
- William T. Hu - Emory UniversityTugba Ozturk - Emory UniversityAlexander Kollhoff - Emory UniversityWhitney Wharton - Emory UniversityJ. Christina Howell - Emory UniversityAlzheimer’s Disease Neuroimaging Initiative
- Contributors
- Del D Miller (Contributor) - University of Iowa, Psychiatry
- Resource Type
- Journal article
- Publication Details
- Nature communications, Vol.12(1), pp.4001-4001
- DOI
- 10.1038/s41467-021-24220-7
- PMID
- 34183654
- PMCID
- PMC8238986
- NLM abbreviation
- Nat Commun
- ISSN
- 2041-1723
- eISSN
- 2041-1723
- Publisher
- Springer Nature
- Number of pages
- 12
- Grant note
- BioClinica, Inc. National Institute of Biomedical Imaging and Bioengineering; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) Eli Lilly and Company; Eli Lilly Fujirebio Araclon Biotech Cogstate; CogState Limited CereSpir, Inc. GE Healthcare; General Electric Meso Scale Diagnostics, LLC. Lundbeck; Lundbeck Corporation F. Hoffmann-La Roche Ltd; Hoffmann-La Roche AbbVie W81XWH-12-2-0012 / DOD; United States Department of Defense EuroImmun Merck Co.; Merck & Company Bobbie Bailey Foundation (Atlanta, GA) Johnson & Johnson Pharmaceutical Research & Development LLC.; Johnson & Johnson; Johnson & Johnson USA Lumosity Biogen Piramal Imaging Servier Canadian Institutes of Health Research; Canadian Institutes of Health Research (CIHR) NeuroRx Research Takeda Pharmaceutical Company; Takeda Pharmaceutical Company Ltd Bristol-Myers Squibb Company; Bristol-Myers Squibb Eisai Inc.; Eisai Co Ltd Alzheimer's Association IXICO Ltd. R01 AG 054046; R21 AG 043885; K01AG042498; U01 AG024904 / NIH; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA Pfizer Inc.; Pfizer Janssen Alzheimer Immunotherapy Research & Development, LLC. Neurotrack Technologies Transition Therapeutics National Institute on Aging; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA) Elan Pharmaceuticals, Inc. Alzheimer's Drug Discovery Foundation Novartis Pharmaceuticals Corporation; Novartis
- Language
- English
- Date published
- 06/28/2021
- Academic Unit
- Psychiatry
- Record Identifier
- 9984280872902771
Metrics
20 Record Views